Virax Biolabs Group is a biotechnology business based in the US. Virax Biolabs Group shares (VRAX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.02 – a decrease of 5.56% over the previous week. Virax Biolabs Group employs 17 staff and has a trailing 12-month revenue of around $84,872.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.02 |
|---|---|
| 52-week range | $0.82 - $7.63 |
| 50-day moving average | $1.08 |
| 200-day moving average | $1.92 |
| Wall St. target price | $3.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.61 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.02 from 2025-05-23
| 1 week (2025-05-16) | -5.56% |
|---|---|
| 1 month (2025-04-25) | -2.86% |
| 3 months (2025-02-25) | -39.64% |
| 6 months (2024-11-25) | -51.66% |
| 1 year (2024-05-24) | 13.33% |
|---|---|
| 2 years (2023-05-24) | -75.45% |
| 3 years (2022-05-21) | N/A |
| 5 years (2020-05-21) | N/A |
| Revenue TTM | $84,872 |
|---|---|
| Gross profit TTM | $33,598 |
| Return on assets TTM | -47.66% |
| Return on equity TTM | -90.64% |
| Profit margin | 0% |
| Book value | $1.99 |
| Market Capitalization | $4.4 million |
TTM: trailing 12 months
We're not expecting Virax Biolabs Group to pay a dividend over the next 12 months.
Virax Biolabs Group's shares were split on a 1:10 basis on 17 December 2023 . So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Virax Biolabs Group shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Virax Biolabs Group shares which in turn could have impacted Virax Biolabs Group's share price.
Over the last 12 months, Virax Biolabs Group's shares have ranged in value from as little as $0.82 up to $7.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Virax Biolabs Group's is 1.822. This would suggest that Virax Biolabs Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Virax Biolabs Group Limited, a biotechnology company, distributes, markets, and sells diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name. It also develops T-Cell IVD test kit for COVID-19, which intend to adapt for immunological profiling against multiple viral threats under the ViraxImmune Brand, as well as a proprietary mobile application for ViraxImmune that presents an individual's immunological profiling data and provide advice on the users' immune system. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, pharmaceutical companies, research institutions, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Learn how and where to buy Fannie Mae (FNMA) stock, view trends and see what may be ahead for share holders.
See how and where to buy Freddie Mac (FMCC) stock, view past price performance and learn what’s ahead for shareholders.
Direct indexing lets you replicate the performance of a specific index with potentially more tax efficiency. Learn how to get started here.
A deep dive into the highlights and limitations of Frec.
Explore the best bonuses for opening a new brokerage account.
It can help reduce taxes owed, but it’s not for beginners.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
The ins and outs of bundling stocks with this accessible investing option.
A deep dive into the highlights and limitations of Robinhood.